Compositions and methods for treating polycystic kidney disease
CA 2348563 A1 · Owner: Genzyme Corporation · Inventors: Petry, Linda R.; Van-Dellen, Katrina; Ibraghimov-Beskrovnaya, Oxana
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides an isolated antibody or fragment thereof that binds to an epitope present in the transmembrane domain of polycystin and specifically recognizes a polycystin-related polypeptide having an apparent molecular weight in the range of about 600 to about 800 kD. Polynucleotides polypeptides, gene delivery vehicles and host cells containing the transmembrane sequences are also provided. Further provided are methods and compositions for modulating the biological activity of polycystin in a suitable cell or tissue.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 25, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 25, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 25, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.